Loading...
XHEL
REG1V
Market cap675mUSD
Dec 05, Last price  
22.15EUR
1D
1.61%
1Q
-5.34%
Jan 2017
118.01%
IPO
3,808.83%
Name

Revenio Group Oyj

Chart & Performance

D1W1MN
XHEL:REG1V chart
P/E
31.86
P/S
5.69
EPS
0.70
Div Yield, %
1.74%
Shrs. gr., 5y
0.69%
Rev. gr., 5y
15.91%
Revenues
104m
+7.17%
22,591,22318,444,36011,456,00045,146,00029,977,00029,434,00033,281,00025,382,00025,727,00016,031,00020,250,00023,434,00026,791,00030,658,00049,474,00061,067,00078,778,00096,976,00096,576,000103,500,000
Net income
18m
-3.20%
002,272,0002,665,000-815,000-507,0003,911,000-287,0004,338,000-694,0006,497,0005,584,0006,850,0008,103,0009,343,00013,362,00017,321,00021,753,00019,109,00018,497,000
CFO
24m
+119.79%
001,001,0003,279,0001,956,0001,274,0004,229,000774,0005,483,0002,763,0006,811,0006,046,0007,870,00010,416,00012,489,00015,230,00021,509,00023,241,00010,862,00023,874,000
Dividend
Apr 05, 20240.38 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Revenio Group Oyj, a health technology company, designs, manufactures, and sells ophthalmic diagnostics and devices for the detection of glaucoma, macular degeneration, diabetic retinopathy, and cataracts in Finland, rest of Europe, and internationally. The company offers iCare IC100 and IC200 tonometers; iCare HOME, a device for self-measurement of eye pressure; imaging devices comprising iCare EIDON AF, a device with confocal retinal imaging; DRSplus, a device for detection of diabetic retinopathy; iCare MAIA, a microperimeter to measure the visual field; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images. It also provides Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities. Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland.
URL
https://www.reveniogroup.fi/
IPO date
Jan 01, 2003
Employees
217
Domiciled in
FI
Incorporated in
FI

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT